SCHEMBL27433652

SCHEMBL27433652

CCOC(=O)c1c(F)c(Cl)cc2c1OCCN2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
ALDH1A1 P00352 2/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
KDM4E B2RXH2 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
RECQL P46063 2/20 0.34
NPC1 O15118 2/20 0.34
TP53 P04637 2/20 0.34
RAB9A P51151 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
MITF O75030 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CYP3A4 P08684 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30954084 1.00 NR1H2 (0.36) NR1H2NR1H3ALDH1A1SLC6A2SLC6A4
SCHEMBL27432951 0.93 ALDH1A1 (0.35) NR1H2NR1H3ALDH1A1SLC6A2SLC6A4
SCHEMBL27432600 0.86 EGFR (0.34) ALDH1A1SLC6A2SLC6A4KDM4ESMN1; SMN2
SCHEMBL30954101 0.86 EGFR (0.34) ALDH1A1SLC6A2SLC6A4KDM4ESMN1; SMN2
SCHEMBL30954117 0.82 HTR4 (0.33) ALDH1A1KDM4ERECQLHSD17B10CYP3A4
SCHEMBL27432616 0.81 EGFR (0.34) ALDH1A1KDM4EHSD17B10MAPT
SCHEMBL30954159 0.81 MAPT (0.36) ALDH1A1KDM4ESMN1; SMN2RECQLNPC1
SCHEMBL30954086 0.80 MAPT (0.35) ALDH1A1KDM4ERECQLNPC1RAB9A
SCHEMBL30954166 0.74 WDR5 (0.33) HSD17B10
SCHEMBL27434138 0.74 LMNA (0.37) NR1H2NR1H3ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP claimed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO claimed
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed